<!DOCTYPE html>
<html lang="en">
<head>
  <!-- Google tag (gtag.js) -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-LSRR4KW715"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());

    gtag('config', 'G-LSRR4KW715');
  </script>


  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Case 18.2 - Post-Menopausal Bleeding</title>

  <!-- Favicon -->
  <link rel="icon" type="image/png" href="../assets/ShepTech logo.png">
  <link rel="apple-touch-icon" href="../assets/ShepTech logo.png">

  <!-- Primary Meta Tags -->
  <meta name="title" content="Case 18.2 - Post-Menopausal Bleeding | MD3 SCP Cases">
  <meta name="description" content="A 62-year-old woman with postmenopausal bleeding - a red flag symptom. Learn about urgent 2WW referral, transvaginal ultrasound, endometrial thickness assessment, endometrial cancer risk factors, and the role of hysteroscopy and biopsy.">

  <!-- Open Graph / Facebook -->
  <meta property="fb:app_id" content="your_facebook_app_id">
  <meta property="og:type" content="article">
  <meta property="og:url" content="https://md3-scp.netlify.app/cases/case18_2.html">
  <meta property="og:title" content="Case 18.2 - Post-Menopausal Bleeding">
  <meta property="og:site_name" content="MD3 SCP Cases">
  <meta property="og:description" content="A 62-year-old woman with postmenopausal bleeding - a red flag symptom. Learn about urgent 2WW referral, transvaginal ultrasound, endometrial thickness assessment, endometrial cancer risk factors, and the role of hysteroscopy and biopsy.">
  <meta property="og:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">
  <!-- Twitter -->
  <meta property="twitter:card" content="summary">
  <meta property="twitter:title" content="Case 18.2 - Post-Menopausal Bleeding">
  <meta property="twitter:description" content="A 62-year-old woman with postmenopausal bleeding - a red flag symptom. Learn about urgent 2WW referral, transvaginal ultrasound, endometrial thickness assessment, endometrial cancer risk factors, and the role of hysteroscopy and biopsy.">
  <meta property="twitter:image" content="https://md3-scp.netlify.app/assets/ShepTech%20logo.png">

  <link rel="stylesheet" href="../css/case.css">

  <!-- Firebase SDK -->
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-app-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-auth-compat.js"></script>
  <script src="https://www.gstatic.com/firebasejs/9.22.0/firebase-firestore-compat.js"></script>
</head>
<body>
  <div class="container">
    <div class="case-header">
      <a href="#" class="back-link" onclick="goBack(event)">← Back to Cases</a>
    </div>

    <h1>Case 18.2 – Post-Menopausal Bleeding</h1>
    <p class="meta"><strong>Category:</strong> Medicine | <strong>Discipline:</strong> Obstetrics & Gynaecology | <strong>Setting:</strong> GP Surgery</p>

    <h2>Case</h2>
    <p>Mrs. Janet Collins, a 62-year-old retired teacher, presents to her GP with a single episode of vaginal bleeding 3 days ago. She describes it as fresh red blood, similar to a light period, requiring the use of sanitary pads for approximately 2 days. She has not had any vaginal bleeding for 11 years (her last menstrual period was aged 51).</p>

    <p>She denies any associated pain, discharge, or weight loss. There is no history of trauma or recent sexual intercourse. She has not experienced any urinary or bowel symptoms. She mentions that she occasionally experiences vaginal dryness but has not sought treatment for this.</p>

    <p>Past medical history includes type 2 diabetes mellitus (managed with metformin), hypertension (on ramipril), and a BMI of 33 (obese). She is a non-smoker and drinks alcohol occasionally. She has never used HRT. She had three vaginal deliveries with no complications. Her last cervical smear 3 years ago was normal. There is no family history of gynaecological cancers.</p>

    <div class="vital-signs">
      <strong>On Examination:</strong>
      <ul>
        <li>General: Appears well, not in distress</li>
        <li>Vital signs: BP 142/88 mmHg, HR 76 bpm, Temperature 36.8°C</li>
        <li>Abdominal examination: Soft, non-tender, no masses palpable, no organomegaly</li>
        <li>Per speculum: Cervix appears healthy, pale vaginal mucosa consistent with atrophy, minimal fresh blood in posterior fornix</li>
        <li>Bimanual: Small anteverted uterus, smooth, mobile, non-tender. No adnexal masses. Fornices clear</li>
      </ul>
    </div>

    <h2>Questions</h2>

        <div class="question">
      <strong>Question 1: What is the significance of postmenopausal bleeding, and what are the key differential diagnoses?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>Definition:</strong> Postmenopausal bleeding (PMB) is any vaginal bleeding occurring ≥12 months after the last menstrual period. It is a <strong>RED FLAG symptom</strong> requiring urgent investigation.</p>

        <p><strong>Significance:</strong></p>
        <ul>
          <li>10% of women with PMB have endometrial cancer</li>
          <li>Risk increases with age, obesity, diabetes, nulliparity, late menopause, unopposed oestrogen exposure</li>
          <li><strong>All PMB requires urgent 2-week-wait (2WW) referral to gynaecology</strong></li>
        </ul>

        <p><strong>Differential Diagnoses (in order of importance):</strong></p>
        <ul>
          <li><strong>Endometrial cancer (10%)</strong>
            <ul>
              <li>Most common gynaecological malignancy in developed countries</li>
              <li>Peak incidence 55-65 years</li>
              <li>Risk factors: obesity, diabetes, nulliparity, late menopause (>55y), unopposed oestrogen (HRT, tamoxifen, PCOS), Lynch syndrome</li>
            </ul>
          </li>
          <li><strong>Atrophic vaginitis (50-60%)</strong> - Most common benign cause
            <ul>
              <li>Low oestrogen → thin, dry vaginal mucosa</li>
              <li>Pale vaginal walls, petechiae, contact bleeding</li>
            </ul>
          </li>
          <li><strong>Endometrial atrophy (15-25%)</strong> - Thin, fragile endometrium</li>
          <li><strong>Endometrial or cervical polyps (10%)</strong> - Usually benign but can bleed</li>
          <li><strong>Endometrial hyperplasia (5-10%)</strong> - Premalignant (especially atypical hyperplasia)</li>
          <li><strong>HRT-related bleeding</strong> - Expected in first 3-6 months of sequential HRT</li>
          <li><strong>Cervical cancer (rare)</strong> - Usually presents with PCB or IMB earlier</li>
          <li><strong>Other:</strong> Submucosal fibroids, bleeding diathesis, anticoagulation</li>
        </ul>

        <p><strong>This patient's risk factors for endometrial cancer:</strong></p>
        <ul>
          <li>Age 62</li>
          <li>Obesity (BMI 33) - adipose tissue converts androgens to oestrogen</li>
          <li>Type 2 diabetes - independent risk factor</li>
          <li>Never used HRT (but no unopposed oestrogen exposure)</li>
        </ul>
      </div>
    </div>

        <div class="question">
      <strong>Question 2: What investigations are required, and what is the management pathway for postmenopausal bleeding?</strong><br>
      <button class="toggle">Show Answer</button>
      <div class="answer">
        <p><strong>Urgent Referral:</strong></p>
        <ul>
          <li><strong>2-week-wait (2WW) referral to gynaecology</strong> - All women with PMB</li>
          <li>Appointment should be within 14 days</li>
        </ul>

        <p><strong>First-Line Investigation (performed in rapid-access clinic):</strong></p>
        <ul>
          <li><strong>Transvaginal ultrasound scan (TVUSS)</strong>
            <ul>
              <li>Measures endometrial thickness (ET)</li>
              <li><strong>ET ≤4mm</strong> → 99% NPV for endometrial cancer (reassuring, low risk)</li>
              <li><strong>ET >4mm</strong> → Further investigation required (endometrial biopsy or hysteroscopy)</li>
              <li>Also assesses ovaries, uterine cavity, polyps, fibroids</li>
            </ul>
          </li>
        </ul>

        <p><strong>Further Investigations (if ET >4mm or TVUSS inconclusive):</strong></p>
        <ul>
          <li><strong>Outpatient hysteroscopy + endometrial biopsy</strong>
            <ul>
              <li>Direct visualization of uterine cavity</li>
              <li>Pipelle biopsy or directed biopsy of abnormal areas</li>
              <li>Gold standard for diagnosis</li>
            </ul>
          </li>
          <li><strong>Alternative:</strong> Blind endometrial biopsy (Pipelle) if hysteroscopy unavailable/declined</li>
        </ul>

        <p><strong>Additional Tests:</strong></p>
        <ul>
          <li>Cervical smear if overdue (though PMB is not usually from cervix)</li>
          <li>STI screen if applicable</li>
        </ul>

        <p><strong>Management Based on Findings:</strong></p>
        <ul>
          <li><strong>ET ≤4mm + benign USS:</strong>
            <ul>
              <li>Low risk for malignancy</li>
              <li>Diagnose atrophic vaginitis/endometrium</li>
              <li>Treat with topical oestrogen (Ovestin cream/pessaries)</li>
              <li>Advise to re-present if bleeding recurs</li>
            </ul>
          </li>
          <li><strong>ET >4mm:</strong>
            <ul>
              <li>Hysteroscopy + biopsy required</li>
              <li>Histology determines management</li>
            </ul>
          </li>
          <li><strong>Endometrial hyperplasia without atypia:</strong>
            <ul>
              <li>Treat with LNG-IUS (Mirena) or continuous progestogens</li>
              <li>Repeat biopsy at 6 months</li>
            </ul>
          </li>
          <li><strong>Atypical hyperplasia:</strong>
            <ul>
              <li>High risk of progression to cancer (25-40%)</li>
              <li>Refer to gynaecology oncology</li>
              <li>Consider hysterectomy (especially if family complete)</li>
            </ul>
          </li>
          <li><strong>Endometrial cancer:</strong>
            <ul>
              <li>Staging MRI pelvis</li>
              <li>MDT discussion</li>
              <li>Treatment: Total abdominal hysterectomy + bilateral salpingo-oophorectomy (TAH+BSO) ± radiotherapy/chemotherapy</li>
            </ul>
          </li>
          <li><strong>Polyps:</strong> Hysteroscopic polypectomy + histology</li>
        </ul>

        <p><strong>This patient's likely pathway:</strong></p>
        <ol>
          <li>Immediate 2WW referral to gynaecology</li>
          <li>TVUSS within 2 weeks</li>
          <li>If ET ≤4mm: Likely atrophic vaginitis → topical oestrogen</li>
          <li>If ET >4mm: Hysteroscopy + biopsy → manage based on histology</li>
        </ol>
      </div>
    </div>

    <h2>Key Learning Points</h2>
    <div class="key-points">
      <ul>
        <li><strong>Postmenopausal bleeding</strong> = any vaginal bleeding ≥12 months after last period - <strong>RED FLAG symptom</strong></li>
        <li><strong>10% of PMB is endometrial cancer</strong> - highest risk in obese, diabetic, nulliparous women</li>
        <li><strong>ALL PMB requires urgent 2-week-wait referral</strong> to gynaecology - no exceptions</li>
        <li><strong>First-line investigation: Transvaginal USS</strong> to measure endometrial thickness (ET)</li>
        <li><strong>ET ≤4mm</strong> = 99% NPV for cancer (reassuring) → likely atrophic changes</li>
        <li><strong>ET >4mm</strong> → Requires hysteroscopy + endometrial biopsy</li>
        <li><strong>Most common cause: Atrophic vaginitis</strong> (50-60%) - treat with topical oestrogen</li>
        <li><strong>Endometrial cancer risk factors:</strong> Age, obesity (BMI >30), diabetes, nulliparity, late menopause (>55y), unopposed oestrogen (HRT, tamoxifen, PCOS), Lynch syndrome</li>
        <li><strong>Atypical hyperplasia</strong> = high risk of progression to cancer (25-40%) → consider hysterectomy</li>
        <li><strong>Never reassure and discharge</strong> without investigation - always refer for TVUSS minimum</li>
      </ul>
    </div>

  </div>

  <!-- JavaScript -->  <script src="../js/firebase-config.js"></script>
  <script src="../js/auth.js"></script>
  <script src="../js/completion-tracker.js"></script>
  <script src="../js/flag-tracker.js"></script>
  <script src="../js/case-interactions.js"></script>

  <script>
    // Toggle case completion
    function toggleCaseCompletion() {
      if (window.completionTracker) {
        const caseId = window.completionTracker.getCurrentCaseId();
        if (caseId) {
          window.completionTracker.toggleCompletion(caseId);
        }
      }
    }// Toggle case flag
    function toggleCaseFlag() {
      console.log('toggleCaseFlag() function called');
      console.log('window.flagTracker exists:', !!window.flagTracker);

      if (!window.flagTracker) {
        console.error('window.flagTracker is not defined!');
        alert('Flag tracker not initialized. Please refresh the page.');
        return;
      }

      const caseId = window.flagTracker.getCurrentCaseId();
      console.log('Current case ID:', caseId);

      if (!caseId) {
        console.error('Could not get case ID');
        alert('Could not determine case ID');
        return;
      }

      console.log('Calling window.flagTracker.toggleCaseFlag with caseId:', caseId);
      window.flagTracker.toggleCaseFlag(caseId);
    }

    // Update case flag button state on page load
    document.addEventListener('DOMContentLoaded', () => {
      if (window.flagTracker) {
        setTimeout(() => {
          const caseId = window.flagTracker.getCurrentCaseId();
          if (caseId) {
            window.flagTracker.updateCaseFlagButton(caseId);
          }
        }, 100);
      }
    });
    }
  </script>

</body>
</html>
